{"id":8259,"date":"2026-05-17T23:26:25","date_gmt":"2026-05-17T20:26:25","guid":{"rendered":"https:\/\/th-option.com\/hims-stock\/"},"modified":"2026-05-17T23:44:59","modified_gmt":"2026-05-17T20:44:59","slug":"hims-stock","status":"publish","type":"post","link":"https:\/\/th-option.com\/en\/hims-stock\/","title":{"rendered":"What is HIMS Stock? An In-Depth Look at Hims &#038; Hers Health \u2014 The Complete Guide to HIMS Stock"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\"  style='background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;'><\/div><div class=\"fusion-builder-row fusion-row \"><\/div><div  class=\"fusion-layout-column fusion_builder_column fusion_builder_column_1_1 fusion-builder-column-0 fusion-one-full fusion-column-first fusion-column-last 1_1\"  style='margin-top:0px;margin-bottom:0px;'><div class=\"fusion-column-wrapper\" style=\"padding: 0px 0px 0px 0px;background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;\"   data-bg-url=\"\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-text\"><\/div><\/p>\n<p>HIMS stock is one of the most-watched equities in global markets in 2024\u20132025, with a price surge of over 2,000% from its all-time low followed by an equally dramatic correction. Many investors still wonder exactly <strong>what HIMS stock is<\/strong>, what the company actually does, and why it attracts so much attention. This guide covers everything you need to know \u2014 from the business fundamentals to the key factors that drive <strong>HIMS stock price<\/strong> movements.<\/p>\n<h2>What Is HIMS Stock? Meet Hims &amp; Hers Health Inc.<\/h2>\n<p><strong>HIMS is the ticker symbol<\/strong> for <strong>Hims &amp; Hers Health, Inc.<\/strong>, a company listed on the New York Stock Exchange (NYSE). The business was founded in 2017 in San Francisco, California by Andrew Dudum and co-founders.<\/p>\n<p>Hims &amp; Hers Health is a telehealth and consumer health company that connects patients with licensed physicians online and delivers prescription medications directly to their door. The company focuses on health categories where people often feel too embarrassed to visit a traditional doctor \u2014 including hair loss, sexual health, skin conditions, mental health, and weight management.<\/p>\n<style>\r\n.center-btn {\r\n  text-align: center;\r\n  margin: 32px 0;\r\n}\r\n\r\n.trade-btn {\r\n  background: #22c55e;              \/* \u0442\u043e\u0439 \u0441\u0430\u043c\u0438\u0439 \u0437\u0435\u043b\u0435\u043d\u0438\u0439 *\/\r\n  color: #ffffff !important;        \/* \u0431\u0456\u043b\u0438\u0439 \u0442\u0435\u043a\u0441\u0442 *\/\r\n  padding: 14px 36px;\r\n  font-size: 16px;                  \/* \u044f\u043a \u0443 CTA *\/\r\n  font-weight: 500;\r\n  text-decoration: none !important;\r\n  border-radius: 10px;              \/* \u0442\u0430 \u0436 \u0433\u0435\u043e\u043c\u0435\u0442\u0440\u0456\u044f *\/\r\n  display: inline-block;\r\n  transition: background-color 0.2s ease;\r\n}\r\n\r\n.trade-btn:hover {\r\n  background: #16a34a;              \/* hover \u044f\u043a \u0443 CTA *\/\r\n}\r\n<\/style>\r\n\r\n<div class=\"center-btn\">\r\n  <a class=\"trade-btn\"\r\n     href=\"https:\/\/affiliate.iqoption.com\/redir\/?aff=12245&instrument=crypto\"\r\n     rel=\"nofollow noopener\">\r\n    IQ OPTION\r\n  <\/a>\r\n<\/div>\n<h3>What Does HIMS Stock Do? The Core Business of Hims &amp; Hers<\/h3>\n<p>The simplest way to think about Hims &amp; Hers is as a full-service online clinic \u2014 one that combines the doctor consultation, the prescription, and the pharmacy delivery into a single seamless experience via a website or mobile app. The core business model is a monthly subscription: customers pay a recurring fee and receive their medications or health products automatically delivered to their home each month.<\/p>\n<p>Current product and service categories at Hims &amp; Hers include the following.<\/p>\n<ul>\n<li><strong>Weight Management<\/strong> \u2014 the top revenue driver today, including GLP-1 medications such as Semaglutide and Novo Nordisk&#8217;s branded Ozempic and Wegovy, plus other weight loss treatments<\/li>\n<li><strong>Hair Loss<\/strong> \u2014 for both men and women, the original product category that launched the company, featuring Finasteride and Minoxidil<\/li>\n<li><strong>Men&#8217;s Sexual Health<\/strong> \u2014 ED medications including Sildenafil (generic Viagra) and Tadalafil (generic Cialis)<\/li>\n<li><strong>Mental Health<\/strong> \u2014 online therapy services and psychiatric medication management<\/li>\n<li><strong>Skincare<\/strong> \u2014 acne treatments, anti-aging creams, and other dermatology products<\/li>\n<li><strong>Women&#8217;s Health<\/strong> \u2014 including perimenopause and menopause treatments launched in 2025<\/li>\n<\/ul>\n<p>What sets Hims &amp; Hers apart from a traditional clinic is that the company removes the barriers to care \u2014 no appointment needed, no travel, and pricing that is more accessible than conventional healthcare. This frictionless model has fueled rapid subscriber growth.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-8253\" src=\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3.webp\" alt=\"What does HIMS stock do business model\" width=\"1376\" height=\"768\" srcset=\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-200x112.webp 200w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-300x167.webp 300w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-400x223.webp 400w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-600x335.webp 600w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-768x429.webp 768w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-800x447.webp 800w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-1024x572.webp 1024w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3-1200x670.webp 1200w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock3.webp 1376w\" sizes=\"auto, (max-width: 1376px) 100vw, 1376px\" \/><\/p>\n<h3>How Did HIMS Stock Enter the Market<\/h3>\n<p>Hims &amp; Hers Health did not go public through a traditional IPO. Instead, it entered the NYSE in January 2021 via a merger with a SPAC (Special Purpose Acquisition Company) called Oaktree Acquisition Corp. Shares started trading at around $10. The stock then endured a brutal decline through 2022 before recovering and surging to an all-time high in 2025.<\/p>\n<h2>HIMS Stock Price \u2014 History and Key Milestones<\/h2>\n<p>The HIMS stock price history is a textbook example of a high-beta growth stock that swings violently in response to news and business developments.<\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>Period<\/strong><\/td>\n<td><strong>Approximate Price<\/strong><\/td>\n<td><strong>Key Event<\/strong><\/td>\n<\/tr>\n<tr>\n<td>January 2021 (first trade)<\/td>\n<td>~$10<\/td>\n<td>Entered market via SPAC merger<\/td>\n<\/tr>\n<tr>\n<td>May 2022 (all-time low)<\/td>\n<td>$2.72<\/td>\n<td>All-time low during broad tech selloff<\/td>\n<\/tr>\n<tr>\n<td>Late 2024<\/td>\n<td>$25\u2013$30<\/td>\n<td>GLP-1 \/ Semaglutide boom drives price higher<\/td>\n<\/tr>\n<tr>\n<td>February 2025 (all-time high)<\/td>\n<td>$72.98<\/td>\n<td>All-time high reached<\/td>\n<\/tr>\n<tr>\n<td>February 2026 (52-week low)<\/td>\n<td>$13.74<\/td>\n<td>FDA removes Semaglutide from shortage list<\/td>\n<\/tr>\n<tr>\n<td>May 2026 (current)<\/td>\n<td>~$25\u2013$30<\/td>\n<td>Recovery following Novo Nordisk partnership<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The table shows just how volatile HIMS stock can be. From its all-time low of $2.72 the stock climbed to $72.98 \u2014 a gain of more than 2,500% \u2014 before falling sharply again. Investors who understand the key drivers behind these moves are better equipped to navigate the volatility.<\/p>\n<h3>Why Did HIMS Stock Surge in 2024\u20132025<\/h3>\n<p>The main factors that pushed HIMS stock sharply higher during 2024\u20132025 were as follows.<\/p>\n<ul>\n<li><strong>The GLP-1 and Semaglutide boom<\/strong> \u2014 when weight loss drugs Ozempic and Wegovy faced shortages in the US, the FDA allowed compounders to produce Compounded Semaglutide. Hims &amp; Hers became one of the largest providers, and revenue from this segment exploded<\/li>\n<li><strong>Revenue growth well above expectations<\/strong> \u2014 full-year 2025 revenue reached $2.35 billion, up 59% year over year, beating analyst forecasts<\/li>\n<li><strong>Subscriber growth<\/strong> \u2014 Q3 2025 subscribers reached 2.5 million, up 21% year over year<\/li>\n<li><strong>First-ever net profit<\/strong> \u2014 the company posted net income of $128 million in 2025, its first profitable year in history<\/li>\n<\/ul>\n<h3>Why Did HIMS Stock Crash in Early 2026<\/h3>\n<p>After reaching the all-time high of $72.98 in February 2025, HIMS stock fell sharply to $13.74 in February 2026. The main reasons were the following.<\/p>\n<ul>\n<li><strong>FDA removed Semaglutide from the shortage list<\/strong> \u2014 once the FDA declared the drug no longer in shortage, Hims &amp; Hers lost the legal ability to compound Semaglutide, eliminating a major revenue stream<\/li>\n<li><strong>Regulatory uncertainty<\/strong> \u2014 investors worried the company could not replace that lost revenue fast enough<\/li>\n<li><strong>Intensifying competition<\/strong> \u2014 rivals including Ro Health, Noom, and other digital health platforms moved aggressively to capture market share<\/li>\n<\/ul>\n<style>\r\n    .center-btn {\r\n        text-align: center;\r\n        margin: 20px 0;\r\n    }\r\n\r\n    .trade-btn {\r\n        background-color: #6ccf84;\r\n        color: #2e3842 !important;   \/* \u041f\u0440\u0438\u043c\u0443\u0441\u043e\u0432\u0438\u0439 \u043a\u043e\u043b\u0456\u0440 *\/\r\n        padding: 14px 36px;\r\n        font-size: 18px;\r\n        font-weight: 600;\r\n        text-decoration: none !important;\r\n        border-radius: 12px;\r\n        display: inline-block;\r\n    }\r\n\r\n    .trade-btn:hover {\r\n        opacity: 0.95;\r\n    }\r\n<\/style>\r\n\r\n<div class=\"center-btn\">\r\n    <a class=\"trade-btn\" href=\"https:\/\/exnova.org\/lp\/start-trading\/?aff=12245&aff_model=revenue&afftrack=\">\r\n        EXNOVA\r\n    <\/a>\r\n<\/div>\n<h2>What Does HIMS Stock Do? Revenue Breakdown<\/h2>\n<p>To fully understand what HIMS stock does, it helps to look at where the money actually comes from.<\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>Revenue Stream<\/strong><\/td>\n<td><strong>Model<\/strong><\/td>\n<td><strong>Example Products<\/strong><\/td>\n<td><strong>Approximate Share<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Online Revenue \u2014 Subscription<\/td>\n<td>Monthly recurring billing<\/td>\n<td>GLP-1 drugs, hair loss meds, ED drugs<\/td>\n<td>~95% of total<\/td>\n<\/tr>\n<tr>\n<td>Online Revenue \u2014 One-time<\/td>\n<td>Single purchase<\/td>\n<td>Skincare products, supplements<\/td>\n<td>Small share<\/td>\n<\/tr>\n<tr>\n<td>Wholesale Revenue<\/td>\n<td>Retail channel sales<\/td>\n<td>Non-prescription products<\/td>\n<td>Small but growing<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The core strength of the Hims &amp; Hers business model is that the vast majority of revenue is recurring subscription income. As the subscriber base grows, cost per customer falls and margins improve over time \u2014 a dynamic that makes the business increasingly capital-efficient at scale.<\/p>\n<h3>Key Financial Figures for HIMS<\/h3>\n<table>\n<tbody>\n<tr>\n<td><strong>Metric<\/strong><\/td>\n<td><strong>2024<\/strong><\/td>\n<td><strong>2025<\/strong><\/td>\n<td><strong>Change<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Total Revenue<\/td>\n<td>$1.48 billion<\/td>\n<td>$2.35 billion<\/td>\n<td>+59%<\/td>\n<\/tr>\n<tr>\n<td>Net Income<\/td>\n<td>Net loss<\/td>\n<td>$128.37 million<\/td>\n<td>First profitable year<\/td>\n<\/tr>\n<tr>\n<td>Subscribers (Q3 2025)<\/td>\n<td>~2 million<\/td>\n<td>2.5 million<\/td>\n<td>+21%<\/td>\n<\/tr>\n<tr>\n<td>Adjusted EBITDA (FY 2025)<\/td>\n<td>Lower<\/td>\n<td>$307\u2013$317 million<\/td>\n<td>Significant increase<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Factors That Drive HIMS Stock Price<\/h2>\n<p>Understanding what moves HIMS stock price helps investors make more informed decisions. The main drivers fall into four categories.<\/p>\n<h3>1. FDA Policy and Regulation<\/h3>\n<p>The single most important driver for HIMS over the past two years has been FDA decisions on GLP-1 medications. When the FDA listed Semaglutide as a shortage drug, Hims &amp; Hers benefited enormously. When the FDA removed it from the shortage list, the stock crashed. Investors must track FDA news closely when holding this stock.<\/p>\n<h3>2. Quarterly Earnings Results<\/h3>\n<p>Every time the company reports earnings, the stock tends to move sharply in either direction. The figures investors watch most closely are total revenue, subscriber growth, and Adjusted EBITDA.<\/p>\n<h3>3. Competition in the Telehealth Market<\/h3>\n<p>The telehealth market is becoming increasingly competitive, with focused health rivals such as Ro Health, Noom, and Teladoc, as well as large platforms like Amazon Pharmacy and CVS Health that could enter the direct-to-consumer prescription market.<\/p>\n<h3>4. Strategic Partnerships<\/h3>\n<p>Deals with major pharmaceutical companies have a significant impact on the stock. The announcement of a partnership with Novo Nordisk to distribute branded GLP-1 drugs in March 2026 led Goldman Sachs and JP Morgan to upgrade the stock to Overweight, triggering a meaningful recovery in the share price.<\/p>\n<h2>HIMS vs Telehealth Competitors<\/h2>\n<table>\n<tbody>\n<tr>\n<td><strong>Company<\/strong><\/td>\n<td><strong>Ticker<\/strong><\/td>\n<td><strong>Key Strengths<\/strong><\/td>\n<td><strong>How It Differs from HIMS<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Hims &amp; Hers Health<\/td>\n<td>HIMS<\/td>\n<td>Direct-to-consumer subscription, affordable pricing, strong brand<\/td>\n<td>Focuses on stigmatized health conditions<\/td>\n<\/tr>\n<tr>\n<td>Teladoc Health<\/td>\n<td>TDOC<\/td>\n<td>Broad telehealth coverage across all conditions<\/td>\n<td>Larger but deeply unprofitable<\/td>\n<\/tr>\n<tr>\n<td>Roman Health (Ro)<\/td>\n<td>Not listed<\/td>\n<td>Similar model to HIMS, men&#8217;s health focus<\/td>\n<td>Private company, not publicly traded<\/td>\n<\/tr>\n<tr>\n<td>Amazon Pharmacy<\/td>\n<td>AMZN<\/td>\n<td>Massive distribution network, competitive pricing<\/td>\n<td>Does not offer telehealth consultations directly<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Pros and Cons of Investing in HIMS Stock<\/h2>\n<h3>Pros of HIMS Stock<\/h3>\n<ul>\n<li><strong>Exceptional revenue growth<\/strong> \u2014 revenue rose 59% in 2025 with a long-term target of $6.5 billion by 2030<\/li>\n<li><strong>Achieved profitability<\/strong> \u2014 net income of $128 million in 2025 for the first time, addressing concerns about cash burn<\/li>\n<li><strong>Subscription model creates predictable recurring revenue<\/strong> \u2014 subscribers tend to stay because they need ongoing medication refills<\/li>\n<li><strong>Telehealth is a long-term secular trend<\/strong> \u2014 consumer appetite for online healthcare accelerated after COVID-19 and shows no sign of reversing<\/li>\n<li><strong>Strong brand recognition<\/strong> \u2014 both the Hims (men) and Hers (women) brands are well recognized in the US market<\/li>\n<\/ul>\n<h3>Cons and Risks of HIMS Stock<\/h3>\n<ul>\n<li><strong>High regulatory risk<\/strong> \u2014 the telehealth business depends heavily on FDA policy and healthcare legislation that can change without warning<\/li>\n<li><strong>Extreme share price volatility<\/strong> \u2014 with a beta of 1.84, HIMS moves nearly twice as much as the broader market<\/li>\n<li><strong>Intensifying competition<\/strong> \u2014 new entrants from both startups and large incumbents are eroding market share<\/li>\n<li><strong>No clear economic moat yet<\/strong> \u2014 Morningstar has not assigned the company a moat rating<\/li>\n<li><strong>Over-reliance on GLP-1 revenue<\/strong> \u2014 FDA policy changes on weight-loss drugs have an outsized impact on business results<\/li>\n<\/ul>\n<h2>HIMS Stock Outlook and Future Targets<\/h2>\n<h3>2026 and 2030 Financial Targets<\/h3>\n<p>The company has published clear financial targets.<\/p>\n<ul>\n<li><strong>2026<\/strong> \u2014 quarterly revenue of $530\u2013$550 million and Adjusted EBITDA <a href=\"https:\/\/th-option.com\/en\/what-is-margin-in-trading\/\">margin<\/a> of 12\u201314%<\/li>\n<li><strong>2030<\/strong> \u2014 annual revenue of at least $6.5 billion and Adjusted EBITDA of at least $1.3 billion<\/li>\n<\/ul>\n<h3>New Strategy After the FDA Semaglutide Rule Change<\/h3>\n<p>After losing the ability to compound Semaglutide, Hims &amp; Hers has laid out a new strategic direction.<\/p>\n<ul>\n<li>Partnership with Novo Nordisk to distribute branded Wegovy and Ozempic officially<\/li>\n<li>Expansion into Eli Lilly&#8217;s Zepbound, despite its high retail price of $1,899 per month<\/li>\n<li>Launch of perimenopause and menopause treatment services to attract a new female subscriber base<\/li>\n<li>International expansion into new markets<\/li>\n<li>Investment in AI and data analytics to deliver more personalized care at scale<\/li>\n<\/ul>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-8255\" src=\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4.webp\" alt=\"HIMS stock outlook future strategy Novo Nordisk\" width=\"1387\" height=\"768\" srcset=\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-200x111.webp 200w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-300x166.webp 300w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-400x221.webp 400w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-600x332.webp 600w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-768x425.webp 768w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-800x443.webp 800w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-1024x567.webp 1024w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4-1200x664.webp 1200w, https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock4.webp 1387w\" sizes=\"auto, (max-width: 1387px) 100vw, 1387px\" \/><\/p>\n<h3>Analyst Views on HIMS Stock Price<\/h3>\n<p>Following the Novo Nordisk partnership announcement in March 2026, several major financial institutions updated their ratings.<\/p>\n<ul>\n<li>Goldman Sachs upgraded from Neutral to Overweight<\/li>\n<li>JP Morgan upgraded from Neutral to Overweight<\/li>\n<li>Analysts noted that legal risk from the compounding business has significantly decreased after the deal<\/li>\n<li>Some firms view HIMS as a potential acquisition target for a company such as CVS Health or Apple<\/li>\n<\/ul>\n<p><strong>Disclaimer:<\/strong> Analyst opinions are not a guarantee of returns. Past stock price performance does not guarantee future results. Always conduct your own research before making any investment decision.<\/p>\n<style>\r\n    .center-btn {\r\n        text-align: center;\r\n        margin: 20px 0;\r\n    }\r\n\r\n    .trade-btn {\r\n        background-color: #6ccf84;\r\n        color: #2e3842 !important;   \/* \u041f\u0440\u0438\u043c\u0443\u0441\u043e\u0432\u0438\u0439 \u043a\u043e\u043b\u0456\u0440 *\/\r\n        padding: 14px 36px;\r\n        font-size: 18px;\r\n        font-weight: 600;\r\n        text-decoration: none !important;\r\n        border-radius: 12px;\r\n        display: inline-block;\r\n    }\r\n\r\n    .trade-btn:hover {\r\n        opacity: 0.95;\r\n    }\r\n<\/style>\r\n\r\n<div class=\"center-btn\">\r\n    <a class=\"trade-btn\" href=\"https:\/\/sabiotrade.com\/?aff=12245&aff_model=revenue&afftrack=\">\r\n        SABIOTRADE\r\n    <\/a>\r\n<\/div>\n<h2>How to Invest in HIMS Stock<\/h2>\n<p>Investors interested in <strong>HIMS stock<\/strong> can access it through several channels.<\/p>\n<h3>Ways to Buy HIMS Stock<\/h3>\n<table>\n<tbody>\n<tr>\n<td><strong>Channel<\/strong><\/td>\n<td><strong>Examples<\/strong><\/td>\n<td><strong>Advantage<\/strong><\/td>\n<td><strong>Watch Out For<\/strong><\/td>\n<\/tr>\n<tr>\n<td>US-based online broker<\/td>\n<td>Interactive Brokers, Fidelity, Charles Schwab<\/td>\n<td>Low fees, full access to NYSE<\/td>\n<td>Must open a brokerage account<\/td>\n<\/tr>\n<tr>\n<td>International broker with US stocks<\/td>\n<td>eToro, Saxo Bank, TD Ameritrade<\/td>\n<td>Available in many countries<\/td>\n<td>Currency conversion costs<\/td>\n<\/tr>\n<tr>\n<td>Healthcare ETF holding HIMS<\/td>\n<td>Select Healthcare ETFs<\/td>\n<td>Built-in diversification<\/td>\n<td>No direct exposure to HIMS specifically<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Key Considerations Before Investing<\/h3>\n<ul>\n<li>Capital gains from foreign stocks may be subject to local tax reporting requirements in your country of residence<\/li>\n<li>US dividend withholding tax of up to 30% applies to non-US investors, though HIMS currently pays no dividend<\/li>\n<li>Currency risk between USD and your local currency can affect real returns<\/li>\n<li>Consult a qualified financial or tax adviser before investing in foreign equities<\/li>\n<\/ul>\n<p><strong>Risk Warning:<\/strong> Investing in stocks involves risk. You may lose all of your invested capital. This content is for general information purposes only and does not constitute financial advice. Always research thoroughly and consult a qualified professional before making any investment decision.<\/p>\n<h2>Summary \u2014 What Is HIMS Stock and Is It Worth Watching<\/h2>\n<p><strong>HIMS stock<\/strong> \u2014 Hims &amp; Hers Health Inc. \u2014 is a fast-growing telehealth company built on a subscription model that makes healthcare more accessible for conditions people are often too embarrassed to discuss openly. The business generated $2.35 billion in revenue in 2025 and achieved net profitability for the first time. However, the stock price remains highly volatile and closely tied to FDA decisions and competitive dynamics.<\/p>\n<p>Key things to remember about HIMS stock.<\/p>\n<ul>\n<li>HIMS is the NYSE ticker for Hims &amp; Hers Health Inc.<\/li>\n<li>The core business is telehealth plus subscription home delivery of prescription medications<\/li>\n<li>Main products include GLP-1 weight loss drugs, hair loss medication, and ED treatments<\/li>\n<li>The all-time high was $72.98 in February 2025<\/li>\n<li>The primary risks are FDA policy changes and intensifying telehealth competition<\/li>\n<li>The 2030 revenue target is $6.5 billion<\/li>\n<\/ul>\n<h2>Frequently Asked Questions About HIMS Stock<\/h2>\n<h3>What is HIMS stock<\/h3>\n<p>HIMS is the NYSE ticker symbol for Hims &amp; Hers Health Inc., a US-based telehealth company that connects patients with licensed physicians online and delivers prescription medications to their homes. The company focuses on health categories that carry social stigma, such as weight management, hair loss, and sexual health.<\/p>\n<h3>What does HIMS stock do<\/h3>\n<p>Hims &amp; Hers operates a direct-to-consumer telehealth platform in the United States. Users consult with doctors online and receive prescription medications on a monthly subscription basis. Current flagship products include GLP-1 weight loss drugs (Semaglutide, Wegovy, Ozempic), hair loss treatments, ED medications, mental health services, and skincare.<\/p>\n<h3>What is the HIMS stock price today<\/h3>\n<p>HIMS stock price changes every trading day. As of May 2026, HIMS was trading at approximately $25\u2013$30 per share, well below its all-time high of $72.98 reached in February 2025. For the current price check Google Finance, Yahoo Finance, or TradingView.<\/p>\n<h3>Why did HIMS stock go up so much in 2024\u20132025<\/h3>\n<p>HIMS stock surged in 2024\u20132025 primarily because of the GLP-1 shortage boom, where the FDA allowed companies to produce compounded versions of Semaglutide. Hims &amp; Hers became a major supplier, driving explosive revenue growth. The stock was also boosted by the company reporting its first-ever net profit in 2025.<\/p>\n<h3>Why did HIMS stock fall in 2026<\/h3>\n<p>HIMS stock dropped sharply in early 2026 after the FDA removed Semaglutide from its drug shortage list. This ended the legal basis for compounding the drug at scale, which had been a central revenue driver. Investors sold the stock on fears that the company could not replace that income quickly, pushing shares from over $70 down to $13.74 in February 2026.<\/p>\n<h3>What type of investor is HIMS stock suited for<\/h3>\n<p>HIMS stock is suited for investors with a high risk tolerance and a long-term investment horizon who believe in the secular growth of telehealth. It is not suitable for investors seeking stability or dividend income. The company currently pays no dividend, and the stock is among the more volatile equities on the NYSE.<\/p>\n<h3>Does HIMS stock pay a dividend<\/h3>\n<p>No. Hims &amp; Hers Health does not pay a dividend. The company reinvests its profits into growth. Returns for investors come entirely from capital appreciation \u2014 the difference between the purchase price and the sale price.<\/p>\n<h3>Can international investors buy HIMS stock<\/h3>\n<p>Yes. International investors can purchase HIMS stock through brokers that provide access to US markets, such as Interactive Brokers, eToro, or Saxo Bank. Be aware of currency conversion costs, local tax reporting obligations on foreign investment gains, and any applicable withholding taxes. Consult a financial or tax adviser before investing.<\/p>\n<p><strong>Risk Warning:<\/strong> The content in this article is for general informational purposes only. It does not constitute financial or investment advice. Investing in stocks involves risk and you may lose all of your capital. Always conduct thorough research and consult a qualified professional before making any investment decision.<\/p>\n<p><strong>You might also be interested in:<\/strong><br \/>\n<a href=\"https:\/\/yourdomain.com\/what-is-pnl\/\">What Is PNL in Trading?<\/a><\/p>\n<p><a href=\"https:\/\/yourdomain.com\/forex-brokers\/\">Best Forex Brokers<\/a><\/p>\n<p><a href=\"https:\/\/yourdomain.com\/what-is-margin\/\">What Is Margin in Trading?<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIMS stock is one of the most-watched equities in global [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8252,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[159],"tags":[],"class_list":["post-8259","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HIMS Stock Explained: What Is Hims &amp; Hers Health and Its Price<\/title>\n<meta name=\"description\" content=\"HIMS stock is Hims &amp; Hers Health \u2014 a fast-growing telehealth company on NYSE. Learn what HIMS does, its stock price history, all-time high, and key risk factors for investors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/th-option.com\/en\/hims-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HIMS Stock Explained: What Is Hims &amp; Hers Health and Its Price\" \/>\n<meta property=\"og:description\" content=\"HIMS stock is Hims &amp; Hers Health \u2014 a fast-growing telehealth company on NYSE. Learn what HIMS does, its stock price history, all-time high, and key risk factors for investors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/th-option.com\/en\/hims-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"th-option.com\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-17T20:26:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-17T20:44:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1387\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Thanakorn\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Thanakorn\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/\"},\"author\":{\"name\":\"Thanakorn\",\"@id\":\"https:\/\/th-option.com\/en\/#\/schema\/person\/caac89baa0cb4a742466a5e58d590159\"},\"headline\":\"What is HIMS Stock? An In-Depth Look at Hims &#038; Hers Health \u2014 The Complete Guide to HIMS Stock\",\"datePublished\":\"2026-05-17T20:26:25+00:00\",\"dateModified\":\"2026-05-17T20:44:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/\"},\"wordCount\":2585,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp\",\"articleSection\":[\"Blog\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/th-option.com\/en\/hims-stock\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/\",\"url\":\"https:\/\/th-option.com\/en\/hims-stock\/\",\"name\":\"HIMS Stock Explained: What Is Hims & Hers Health and Its Price\",\"isPartOf\":{\"@id\":\"https:\/\/th-option.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp\",\"datePublished\":\"2026-05-17T20:26:25+00:00\",\"dateModified\":\"2026-05-17T20:44:59+00:00\",\"author\":{\"@id\":\"https:\/\/th-option.com\/en\/#\/schema\/person\/caac89baa0cb4a742466a5e58d590159\"},\"description\":\"HIMS stock is Hims & Hers Health \u2014 a fast-growing telehealth company on NYSE. Learn what HIMS does, its stock price history, all-time high, and key risk factors for investors.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/th-option.com\/en\/hims-stock\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage\",\"url\":\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp\",\"contentUrl\":\"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp\",\"width\":1387,\"height\":768,\"caption\":\"\u0e2b\u0e38\u0e49\u0e19 HIMS \u0e04\u0e37\u0e2d\u0e2d\u0e30\u0e44\u0e23?\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/th-option.com\/en\/#website\",\"url\":\"https:\/\/th-option.com\/en\/\",\"name\":\"th-option.com\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/th-option.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/th-option.com\/en\/#\/schema\/person\/caac89baa0cb4a742466a5e58d590159\",\"name\":\"Thanakorn\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/th-option.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96711dc846a1c4ce1510ff3fcedd38bef5a9d3dceb3ae68df7678c6cfed72cda?s=96&d=https%3A%2F%2Fth-option.com%2Fwp-content%2Fuploads%2F2025%2F09%2Fauthor-150x150.jpg&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96711dc846a1c4ce1510ff3fcedd38bef5a9d3dceb3ae68df7678c6cfed72cda?s=96&d=https%3A%2F%2Fth-option.com%2Fwp-content%2Fuploads%2F2025%2F09%2Fauthor-150x150.jpg&r=g\",\"caption\":\"Thanakorn\"},\"description\":\"Hi, my name is Van, but I am better known as Thanakorn. I am originally from Hue, Vietnam. When I was 19 years old, I watched a YouTube video that caught my interest. Since then, I have been seriously studying this topic and created my own website and blog to share my knowledge and investment experience. I have been working with options and cryptocurrency for over 8 years and I am constantly updating my content to help readers learn and understand the world of investing in a clear way.\",\"url\":\"https:\/\/th-option.com\/en\/author\/thanakorn\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HIMS Stock Explained: What Is Hims & Hers Health and Its Price","description":"HIMS stock is Hims & Hers Health \u2014 a fast-growing telehealth company on NYSE. Learn what HIMS does, its stock price history, all-time high, and key risk factors for investors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/th-option.com\/en\/hims-stock\/","og_locale":"en_US","og_type":"article","og_title":"HIMS Stock Explained: What Is Hims & Hers Health and Its Price","og_description":"HIMS stock is Hims & Hers Health \u2014 a fast-growing telehealth company on NYSE. Learn what HIMS does, its stock price history, all-time high, and key risk factors for investors.","og_url":"https:\/\/th-option.com\/en\/hims-stock\/","og_site_name":"th-option.com","article_published_time":"2026-05-17T20:26:25+00:00","article_modified_time":"2026-05-17T20:44:59+00:00","og_image":[{"width":1387,"height":768,"url":"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp","type":"image\/webp"}],"author":"Thanakorn","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Thanakorn","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/th-option.com\/en\/hims-stock\/#article","isPartOf":{"@id":"https:\/\/th-option.com\/en\/hims-stock\/"},"author":{"name":"Thanakorn","@id":"https:\/\/th-option.com\/en\/#\/schema\/person\/caac89baa0cb4a742466a5e58d590159"},"headline":"What is HIMS Stock? An In-Depth Look at Hims &#038; Hers Health \u2014 The Complete Guide to HIMS Stock","datePublished":"2026-05-17T20:26:25+00:00","dateModified":"2026-05-17T20:44:59+00:00","mainEntityOfPage":{"@id":"https:\/\/th-option.com\/en\/hims-stock\/"},"wordCount":2585,"commentCount":0,"image":{"@id":"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp","articleSection":["Blog"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/th-option.com\/en\/hims-stock\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/th-option.com\/en\/hims-stock\/","url":"https:\/\/th-option.com\/en\/hims-stock\/","name":"HIMS Stock Explained: What Is Hims & Hers Health and Its Price","isPartOf":{"@id":"https:\/\/th-option.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage"},"image":{"@id":"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp","datePublished":"2026-05-17T20:26:25+00:00","dateModified":"2026-05-17T20:44:59+00:00","author":{"@id":"https:\/\/th-option.com\/en\/#\/schema\/person\/caac89baa0cb4a742466a5e58d590159"},"description":"HIMS stock is Hims & Hers Health \u2014 a fast-growing telehealth company on NYSE. Learn what HIMS does, its stock price history, all-time high, and key risk factors for investors.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/th-option.com\/en\/hims-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/th-option.com\/en\/hims-stock\/#primaryimage","url":"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp","contentUrl":"https:\/\/th-option.com\/wp-content\/uploads\/2026\/05\/hims-stock2.webp","width":1387,"height":768,"caption":"\u0e2b\u0e38\u0e49\u0e19 HIMS \u0e04\u0e37\u0e2d\u0e2d\u0e30\u0e44\u0e23?"},{"@type":"WebSite","@id":"https:\/\/th-option.com\/en\/#website","url":"https:\/\/th-option.com\/en\/","name":"th-option.com","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/th-option.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/th-option.com\/en\/#\/schema\/person\/caac89baa0cb4a742466a5e58d590159","name":"Thanakorn","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/th-option.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96711dc846a1c4ce1510ff3fcedd38bef5a9d3dceb3ae68df7678c6cfed72cda?s=96&d=https%3A%2F%2Fth-option.com%2Fwp-content%2Fuploads%2F2025%2F09%2Fauthor-150x150.jpg&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96711dc846a1c4ce1510ff3fcedd38bef5a9d3dceb3ae68df7678c6cfed72cda?s=96&d=https%3A%2F%2Fth-option.com%2Fwp-content%2Fuploads%2F2025%2F09%2Fauthor-150x150.jpg&r=g","caption":"Thanakorn"},"description":"Hi, my name is Van, but I am better known as Thanakorn. I am originally from Hue, Vietnam. When I was 19 years old, I watched a YouTube video that caught my interest. Since then, I have been seriously studying this topic and created my own website and blog to share my knowledge and investment experience. I have been working with options and cryptocurrency for over 8 years and I am constantly updating my content to help readers learn and understand the world of investing in a clear way.","url":"https:\/\/th-option.com\/en\/author\/thanakorn\/"}]}},"_links":{"self":[{"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/posts\/8259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/comments?post=8259"}],"version-history":[{"count":3,"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/posts\/8259\/revisions"}],"predecessor-version":[{"id":8260,"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/posts\/8259\/revisions\/8260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/media\/8252"}],"wp:attachment":[{"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/media?parent=8259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/categories?post=8259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/th-option.com\/en\/wp-json\/wp\/v2\/tags?post=8259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}